FDA OFFERS TIPS ON HANDLING BA, BE TESTING SAMPLES
The FDA has issued a final guidance on how drugmakers, laboratories and others should handle reserve testing samples for bioavailabilty (BA) and bioequivalence (BE) studies used to support new and generic drug applications.
300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.
Phone (703) 538-7600 - Fax (703) 538-7676 - Toll free (888) 838-5578.
Copyright by FDAnews. All rights reserved. Do not duplicate or redistribute in any form.